Related Experiment Videos
Ceftriaxone in the treatment of infections caused by Staphylococcus aureus in children
Insights
Ceftriaxone effectively treated Staphylococcus aureus infections in children. This new cephalosporin antibiotic demonstrated safety and efficacy as a single agent for pediatric Gram-positive bacterial infections.
Area of Science:
- Pediatric Infectious Diseases
- Bacteriology
- Pharmacology
Background:
- Ceftriaxone is a parenteral cephalosporin with broad-spectrum activity.
- Its efficacy against Gram-positive organisms, specifically Staphylococcus aureus, needed further investigation for single-agent use.
- Staphylococcus aureus infections in children require effective and safe treatment options.
Purpose of the Study:
- To evaluate the safety and efficacy of ceftriaxone as a single antibiotic for treating pediatric infections caused by Staphylococcus aureus.
- To assess clinical and bacteriologic outcomes in children receiving ceftriaxone for S. aureus infections.
Main Methods:
- A study involving 12 pediatric patients with S. aureus infections was conducted.
- Patients received ceftriaxone at doses of 68 to 100 mg/kg/day in two divided doses for 3 to 20 days.
- Infections included soft tissue, respiratory tract, and bone and joint sites.
Main Results:
- All 12 patients showed satisfactory clinical and bacteriologic responses to ceftriaxone treatment.
- Adverse events were generally mild and transient, including abdominal pain, skin rash, elevated platelet counts, eosinophilia, and transient neutropenia.
- All reported abnormalities resolved during or after therapy.
Conclusions:
- Ceftriaxone is a safe and effective single antibiotic for treating pediatric S. aureus infections.
- The drug's prolonged half-life and expanded Gram-negative spectrum, combined with its efficacy against S. aureus, make it a valuable therapeutic option.
- Further research may explore its use in mixed infections and other pediatric bacterial infections.
Abstract:
Ceftriaxone is a new parenteral cephalosporin with a prolonged half-life and an expanded Gram-negative spectrum. Before it can be used as a single agent for infections of unknown etiology, its efficacy in treating infections caused by Gram-positive organisms, particularly Staphylococcus aureus, must be proven. Ceftriaxone was administered to 12 children for treatment of infections due to S. aureus alone or in the presence of other organisms. Sites of infection included soft tissue, respiratory tract, bone and joint. Patients received ceftriaxone at 68 to 100 mg/kg/day in two doses for 3 to 20 days. Clinical and bacteriologic responses were satisfactory in all patients. One patient experienced abdominal pain during infusion and another developed a skin rash. Five patients had platelet counts of 500,000/mm3 or greater; four had an eosinophil count of 7% or greater and one patient had transient neutropenia. These abnormalities resolved during or after therapy. Ceftriaxone was a safe and effective single antibiotic for the treatment of infections caused by S. aureus in children.